Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
SCI Journal - SKI-G-8... 2022.02.16  
FLT3/AXL Inhibitor (A... 2020.06.22  
  1. No Image 01Jun
    by

    Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech

  2. No Image 01Jun
    by

    Yuhan ups investment in biotechs for immuno-oncology drug push

  3. No Image 01Jun
    by

    "ASCO 2018: Genosco/Yuhan Announce Results from Phase 1/2 Study of Lazertinib (YH25448, GNS-1480), a 3rd-Generation EGFR-TKI, in Advanced NSCLC"

  4. No Image 01Jun
    by

    Genosco/Yuhan Announce Results from Phase 1/2 Study of YH25448, a 3rd-Generation EGFR-TKI, in Advanced NSCLC to be Presented at ASCO 2018

  5. No Image 01Jun
    by

    More than half of Korean biopharma firms view R&D investments as assets.

  6. No Image 01Jun
    by

    Oscotec shares rebound on launch of US clinical trial

  7. No Image 01Jun
    by

    INTERVIEW: Oscotec Lays Out Global Ambitions For RA, Cancer Drugs

  8. No Image 01Jun
    by

    Oscotec`s SYK inhibitor Program Gets Korea Drug Fund Money

  9. No Image 01Jun
    by

    G-749, a novel FLT3 Kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.

  10. No Image 01Jun
    by

    Profiles of Four New Stock-Billionaires

  11. No Image 01Jun
    by

    IPOs spawn instant billionaires

Board Pagination Prev 1 2 Next
/ 2
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.